Q1 Earnings Forecast for CRDF Issued By William Blair

Cardiff Oncology, Inc. (NASDAQ:CRDF) – William Blair issued their Q1 2026 earnings per share (EPS) estimates for Cardiff Oncology in a research report issued on Thursday, February 27th. William Blair analyst A. Hsieh anticipates that the company will post earnings of ($0.26) per share for the quarter. The consensus estimate for Cardiff Oncology’s current full-year earnings is ($0.99) per share. William Blair also issued estimates for Cardiff Oncology’s Q2 2026 earnings at ($0.26) EPS, Q3 2026 earnings at ($0.28) EPS and Q4 2026 earnings at ($0.28) EPS.

CRDF has been the topic of several other research reports. Piper Sandler lifted their price objective on Cardiff Oncology from $7.00 to $10.00 and gave the stock an “overweight” rating in a report on Friday, December 13th. HC Wainwright upped their target price on Cardiff Oncology from $13.00 to $17.00 and gave the stock a “buy” rating in a report on Friday, February 28th.

Cardiff Oncology Trading Down 2.4 %

CRDF opened at $3.73 on Monday. The company has a market cap of $190.73 million, a P/E ratio of -3.97 and a beta of 1.77. The business’s 50-day moving average price is $4.05 and its 200-day moving average price is $3.26. Cardiff Oncology has a 12 month low of $2.01 and a 12 month high of $6.42.

Insider Transactions at Cardiff Oncology

In other Cardiff Oncology news, Director Gary W. Pace acquired 350,115 shares of the stock in a transaction that occurred on Wednesday, December 11th. The shares were acquired at an average cost of $2.60 per share, with a total value of $910,299.00. Following the transaction, the director now owns 1,047,876 shares of the company’s stock, valued at $2,724,477.60. The trade was a 50.18 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 7.80% of the company’s stock.

Hedge Funds Weigh In On Cardiff Oncology

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Invst LLC raised its stake in Cardiff Oncology by 60.0% during the 4th quarter. Invst LLC now owns 36,000 shares of the company’s stock valued at $156,000 after buying an additional 13,500 shares during the last quarter. Parr Mcknight Wealth Management Group LLC bought a new position in Cardiff Oncology in the 4th quarter worth $69,000. AWM Investment Company Inc. bought a new position in Cardiff Oncology in the 4th quarter worth $462,000. Shay Capital LLC bought a new position in Cardiff Oncology in the 4th quarter worth $91,000. Finally, Point72 Asset Management L.P. bought a new stake in Cardiff Oncology during the fourth quarter valued at about $2,207,000. 16.29% of the stock is owned by institutional investors.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.